Intranasal and Intramuscular Immunization with Outer Membrane Vesicles from Serogroup C Meningococci Induced Functional Antibodies and Immunologic Memory

References

• Acevedo R, Fernández S, Zayas C, Acosta A, Sarmiento ME, Ferro VA, Rosenqvist E, Campa C, Cardoso D, and Garcia L, et al. 2014. Bacterial outer membrane vesicles and vaccine applications. Front Immunol. 5:1–6.
   PubMed Web of Science ®Google Scholar
• Arlian BM, Tinker JK. 2011. Mucosal immunization with a Staphylococcus aureus IsdA-cholera toxin a 2/B chimera induces antigen-specific Th2-type responses in mice. Clin Vaccine Immunol. 18:1543–51.
   PubMedGoogle Scholar
• Arunachalam AB, Vile S, Rosas A. 2022. A mouse immunogenicity model for the evaluation of meningococcal conjugate vaccines. Front Immunol. 13:1–11.
   Web of Science ®Google Scholar
• Balhuizen MD, Veldhuizen EJA, Haagsman HP. 2021. Outer membrane vesicle induction and isolation for vaccine development. Front Microbiol. 12. doi:10.3389/fmicb.2021.629090
   PubMed Web of Science ®Google Scholar
• Biolchi A, De Angelis G, Moschioni M, Tomei S, Brunelli B, Giuliani M, Bambini S, Borrow R, Claus H, Gorlaa MC, Hong E. 2020a. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates. Vaccine. 38:7542–50.
   PubMed Web of Science ®Google Scholar
• Biolchi A, De Angelis G, Moschioni M, Tomei S, Brunelli B, Giuliani M, Bambini S, Borrow R, Claus H, Gorla MC, et al. 2020b. 4CMenB immunization induces serum bactericidal antibodies against non-serogroup B meningococcal strains in adolescents. Infect Dis Ther. doi:10.1007/s40121-020-00370-x
   PubMed Web of Science ®Google Scholar
• Biozzi G, Stiffel C, Mouton D, Bouthillier Y, Decreusefond C. 1968. A kinetic study of antibody producing cells in the spleen of mice immunized intravenously with sheep erythrocytes. Immunol. 14:7–20.
   PubMed Web of Science ®Google Scholar
• Biozzi BYG, Stiffel C, Mouton D, Bouthillier Y, Decreusefond C. 1972. Cytodynamics of the immune response in two lines of mice genetically selected for ”high” and ”low” antibody synthesis. J Exp Med. 135:1071–94. doi:10.1084/jem.135.5.1071.
   PubMed Web of Science ®Google Scholar
• Borrow R, Alarcón P, Carlone GM, Caugant DA, Christensen H, Debbag R, De Wals P, Echániz-Aviles G, Findlow J, Head C, et al. 2003. Serogroup B and C serum bactericidal assays. Meningococcal Vaccines. 66:289–304.
   Google Scholar
• Borrow R, Alarcón P, Carlos J, Caugant DA, Christensen H, Debbag R, De Wals P, Echániz-Aviles G, Findlow J, Head C, et al. 2017. The global meningococcal initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 16:313–28.
   PubMed Web of Science ®Google Scholar
• Brookes C, Kuisma E, Alexander F, Allen L, Tipton T, Ram S, Gorringe A, Taylor S. 2013. Development of a large scale human complement source for use in bacterial immunoassays. J Immunol Methods. 391:39–49.
   PubMed Web of Science ®Google Scholar
• Carmo AMS, Ferraz AS, Yto AY, Neri S, Cunha TN, Gaspari END. 2009. Prime-boost immunogenicity of class 5C protein from Neisseria meningitidis in mice with different adjuvants. Open Vaccine J. 2:45–55.
   Google Scholar
• Cedré B, Hernández Y, Delgado I, Izquierdo L, García L. 2012. Validación del ensayo bactericida en suero para los serogroups A, C y W 135 de Neisseria meningitidis. Vaccimonitor. 21:31–34.
   Google Scholar
• Cesta MF. 2006. Normal structure, function, and histology of the spleen. Toxicol Pathol. 34:455–65.
   PubMed Web of Science ®Google Scholar
• Chackerian B, Lowy DR, Schiller JT. 2001. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest. 108:415–23.
   PubMed Web of Science ®Google Scholar
• Comanducci M, Bambini S, Brunelli B, Adu-Bobie J, Aricò B, Capecchi B, Giuliani MM, Masignani V, Santini L, Savino S, et al. 2002. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med. 195:1445–54.
   PubMed Web of Science ®Google Scholar
• Correa VA, Rodrigues TS, Portilho AI, de Lima GT, De Gaspari E. 2021. Modified ELISA for antibody avidity evaluation: the need for standardization. Biomed J. 44:433–38.
   PubMed Web of Science ®Google Scholar
• Currie EG, Gray-Owen SD. 2021. Exploring the ability of meningococcal vaccines to elicit mucosal immunity: insights from humans and mice. Pathogens. 10:906.
   PubMed Web of Science ®Google Scholar
• Dalseg R, Wedege E, Holst J, Haugen IL, Høiby EA. 1999. Outer membrane vesicles of group B meningococci are strongly immunogenic when given intranasally to mice. Vaccine. 17:2336–45.
   PubMed Web of Science ®Google Scholar
• Danve B, Lissolo L, Mignon M, Dumas P, Colombani S, Schryvers AB, Quentin-Millet M-J. 1993. Transferrin-binding proteins isolated from Neisseria meningitidis elicit protective and bactericidal antibodies in laboratory animals. Vaccine. 11:1214–20.
   PubMed Web of Science ®Google Scholar
• De Gaspari E, Zollinger W. 2001. Expression of class 5 antigens by meningococcal strains obtained from patients in Brazil and evaluation of two new monoclonal antibodies. Braz J Infect Dis. 5:143–53.
   PubMedGoogle Scholar
• De Gaspari E. 2012. Application of prime-boost as a novel vaccination strategy against microbial pathogens. In: Méndez-Vilas A, editor. Science against microbial pathogens: communicating current research and technological advances. Badajoz, Spain: Formatex. p. 422–28.
   Google Scholar
• de Oliveira Santos FA, Lincopan N, De Gaspari E. 2018. Evaluation of intranasal and subcutaneous route of immunization in neonatal mice using DODAB-BF as adjuvant with outer membrane vesicles of Neisseria meningitis B. Immunobiol. 223:750–60.
   PubMed Web of Science ®Google Scholar
• Dimitrov JD, Lacroix-Desmazes S, Kaveri SV. 2011. Important parameters for evaluation of antibody avidity by immunosorbent assay. Anal Biochem. 418:149–51.
   PubMed Web of Science ®Google Scholar
• Ferreirós C, Ferreiro N, Criado MT. 2002. Influence of adjuvants on the ability of anti-Tbp antibodies to block transferrin binding, iron uptake and growth of Neisseria meningitidis. Enferm Infecc Microbiol Clin. 20:316–20.
   PubMed Web of Science ®Google Scholar
• Gaspar EB, Rosetti AS, Lincopan N, De Gaspari E. 2013. Neisseria lactamica antigens complexed with a novel cationic adjuvant. Hum Vaccines Immunother. 9:572–81.
   PubMed Web of Science ®Google Scholar
• Gaspar EB, Prudencio CR, De Gaspari E. 2021. Experimental studies using OMV in a new platform of SARS-CoV-2 vaccines. Hum Vaccines Immunother. 17:2965–68.
   PubMed Web of Science ®Google Scholar
• González-Miró M, Rodríguez-Noda LM, Fariñas-Medina M, Cedré-Marrero B, Madariaga-Zarza S, Zayas-Vignier C, Hernández-Cedeño M, Kleffmann T, García-Rivera D, Vérez-Bencomo V, et al. 2018. Bioengineered polyester beads co-displaying protein and carbohydrate-based antigens induce protective immunity against bacterial infection. Sci Rep. 8:1–15.
   PubMed Web of Science ®Google Scholar
• Gorla MC, Brandao AP, Pinhata JMW, de Moraes C, Pereira G, Lemos AP. 2020. Phenotypic characterization of Neisseria meningitidis strains isolated from invasive meningococcal disease in Brazil from 2002 to 2017. Access Microbiol. 2. doi:10.1099/acmi.0.000079
   PubMedGoogle Scholar
• Granoff DM, Maslanka SE, Carlone GM, Plikaytis BD, Santos GF, Mokatrin A, Raff HV. 1998. A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses. Clin Diagn Lab Immunol. 5:479–85.
   PubMedGoogle Scholar
• Granoff DM 2009. Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease. Vaccine. 27. doi:10.1016/J.VACCINE.2009.04.066
   PubMed Web of Science ®Google Scholar
• He P, Zou Y, Hu Z. 2015. Advances in aluminum hydroxide-based adjuvant research and its mechanism. Hum Vaccines Immunother. 11:477–88.
   PubMed Web of Science ®Google Scholar
• Holmgren J, Lycke N, Czerkinsky C. 1993. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine. 11:1179–84.
   PubMed Web of Science ®Google Scholar
• Hou Y, Yan T, Cao H, Liu P, Zheng K, Li Z, Deng Q, Hu S. 2019. Chimeric hepatitis B virus core particles displaying Neisserial surface protein a confer protection against virulent Neisseria meningitidis serogroup B in BALB/c mice. Int J Nanomed. 14:6601–13.
   PubMed Web of Science ®Google Scholar
• Ito AY, Néri S, Machado MSS, Tunes CF, De Gaspari EN. 2009. Homologous prime-boost strategy in neonate mice using Neisseria lactamica. Vaccine. 27:3422–28.
   PubMed Web of Science ®Google Scholar
• Kelly SM, Larsen KR, Darling R, Petersen AC, Bellaire BH, Wannemuehler MJ, Narasimhan B. 2021. Single-dose combination nanovaccine induces both rapid and durable humoral immunity and toxin neutralizing antibody responses against bacillus anthracis. Vaccine. 39:3862–70.
   PubMed Web of Science ®Google Scholar
• Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:680–85.
   PubMed Web of Science ®Google Scholar
• Lavelle EC, Ward RW. 2021. Mucosal vaccines — fortifying the frontiers. Nat Rev Immunol. 0123456789. doi:10.1038/s41577-021-00583-2
   Google Scholar
• Lemos APS, Harrison LH, Lenser M, Sacchi CT. 2010. Phenotypic and molecular characterization of invasive serogroup W135 Neisseria meningitidis strains from 1990 to 2005 in Brazil. J Infect. 60:209–17.
   PubMed Web of Science ®Google Scholar
• Li Z, Li Y, Wang Y, Hou Y, Cao H, Wu X, Hu S, Long D. 2021. Intranasal immunization with a rNMB0315 and combination adjuvants induces protective immunity against Neisseria meningitidis serogroup B in mice. Int Immunopharmacol. 93:107411.
   PubMed Web of Science ®Google Scholar
• Luijkx TA. 2006. Immunogenicity of meningococcal PorA antigens in OMV vaccines.
   Google Scholar
• Mosmann TRM, Coffman RL. 1989. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 7:145–73.
   PubMed Web of Science ®Google Scholar
• Mustapha MM, Marsh JW, Krauland MG, Fernandez JO, de Lemos APS, Dunning Hotopp JC, Wang X, Mayer LW, Lawrence JG, Hiller NL. 2015. Genomic epidemiology of hypervirulent serogroup W, ST-11 Neisseria meningitidis. EBioMedicine. 2:1447–55.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. 2005. Immunology: divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science (80-). 310:1510–12.
   PubMed Web of Science ®Google Scholar
• Olivera N, Castuma CE, Hozbor D, Gaillard ME, Rumbo M, Gómez RM. 2014. Immunization with the recombinant cholera toxin B fused to fimbria 2 protein protects against bordetella pertussis infection. Biomed Res Int. 2014. doi:10.1155/2014/421486
   PubMed Web of Science ®Google Scholar
• Petousis-Harris H, Paynter J, Morgan J, Saxton P, McArdle B, Goodyear-Smith F, Black S. 2017. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet. 390:1603–10.
   PubMed Web of Science ®Google Scholar
• Pizza M, Bekkat-Berkani R, Rappuoli R. 2020. Vaccines against meningococcal diseases. Microorganisms. 8:1–21.
   Web of Science ®Google Scholar
• Pollard AJ, Frasch C. 2001. Development of natural immunity to Neisseria meningitidis. Vaccine. 19:1327–46.
   PubMed Web of Science ®Google Scholar
• Poolman JT. 2020. Expanding the role of bacterial vaccines into life-course vaccination strategies and prevention of antimicrobial-resistant infections. Npj Vaccines. 5. doi:10.1038/s41541-020-00232-0
   PubMed Web of Science ®Google Scholar
• Presa JV, de Almeida RS, Spinardi JR, Cane A. 2019. Epidemiological burden of meningococcal disease in Brazil: a systematic literature review and database analysis. Int J Infect Dis. 80:137–46.
   PubMed Web of Science ®Google Scholar
• Reyes LM, Lastre M, Cuello M, Cabrera O, Borrego Y, Pupo RR, Black S, Pérez O. 2020. Adjuvants derived from Neisseria meningitidis serogroup B induce a cross reactive response against Neisseria gonorrhoeae in mice. Open J Immunol. 10:47–58.
   Google Scholar
• Rouphael NG, Stephens DS. 2012. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol. 799:1–20.
   PubMedGoogle Scholar
• Sacchi CT, De Lemos APS, Camargo MCC, Whitney AM, Melles CE, Solari CA, Frasch CE, Mayer LW. 1998. Meningococcal disease caused by Neisseria meningitidis serogroup B serotype 4 in São Paulo, Brazil, 1990 to 1996. Rev Inst Med Trop Sao Paulo. 40:65–70.
   PubMedGoogle Scholar
• Sasaki K, Kato M, Takahashi T, Ochi S, Ichinose Y, Shiraki K, Asano Y, Iwanaga M, Tsuji T. 2003. Live varicella vaccine polarizes the mucosal adjuvant action of cholera toxin or its B subunit on specific Th1-type helper T cells with a single nasal coadministration in mice. J Med Virol. 70:329–35.
   PubMed Web of Science ®Google Scholar
• Sasaki S, Sullivan M, Narvaez CF, Holmes TH, Furman D, Zheng NY, Nishtala M, Wrammert J, Smith K, James JA, Dekker CL. 2011. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Invest. 121:3109–19.
   PubMed Web of Science ®Google Scholar
• Savelkoul HFJ, Ferro VA, Strioga MM, Schijns VE. 2015. Choice and design of adjuvants for parenteral and mucosal vaccines. Vaccines. 3:148–71.
   PubMed Web of Science ®Google Scholar
• Seidal T, Balaton AJ, Battifora H. 2001. Interpretation and quantification of immunostains. Am J Surg Pathol. 25:1204–07.
   PubMed Web of Science ®Google Scholar
• Shah RR, Hassett KJ, Brito LA. 2017. Overview of vaccine adjuvants: Introduction, history, and current status. Methods Mol Biol. 1494:1–13.
   PubMedGoogle Scholar
• Silva FC, Gioia CA, Oliveira JM, Cruz SD, Frasch CE, Milagres LG. 2007. Differential capacities of outer membrane proteins from Neisseria meningitidis B to prime the murine immune system after vaccination. Scand J Immunol. 65:1–7.
   PubMed Web of Science ®Google Scholar
• Stiasny K, Aberle JH, Keller M, Grubeck-Loebenstein B, Heinz FX. 2012. Age affects quantity but not quality of antibody responses after vaccination with an inactivated flavivirus vaccine against tick-borne encephalitis. PLoS One. 7:1–7.
   Web of Science ®Google Scholar
• Stratmann T. 2015. Cholera toxin subunit b as adjuvant—an accelerator in protective immunity and a break in autoimmunity. Vaccines. 3:579–96.
   PubMedGoogle Scholar
• Sun X, Stefanetti G, Berti F, Kasper DL. 2019. Polysaccharide structure dictates mechanism of adaptive immune response to glycoconjugate vaccines. Proc Natl Acad Sci U S A. 116:193–98.
   PubMed Web of Science ®Google Scholar
• Trzewikoswki de Lima G, De Gaspari E. 2019. Study of the immune response in the elderly: Is it necessary to develop a vaccine against Neisseria meningitidis for the aged? J Aging Res. 2019. doi:10.1155/2019/9287121
   PubMedGoogle Scholar
• Trzewikoswki de Lima G, Rodrigues TS, Portilho AI, Correa VA, Gaspar EB, De Gaspari E 2020. Immune responses of meningococcal B outer membrane vesicles in middle-aged mice. Pathog Dis. 78:ftaa028.
   PubMed Web of Science ®Google Scholar
• Tzeng YL, Thomas J, Stephens DS. 2016. Regulation of capsule in Neisseria meningitidis. Crit Rev Microbiol. 42:759–72.
   PubMed Web of Science ®Google Scholar
• Urwin R, Russell JE, Thompson EAL, Holmes EC, Feavers IM, Maiden MC. 2004. Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect Immun. 72:5955–62.
   PubMed Web of Science ®Google Scholar
• Vermont CL, Van Dijken HH, Van Limpt CJ, de Groot R, van Alphen L, van den Dobbelsteen GP. 2002. Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine. Infect Immun. 70:584–90.
   PubMed Web of Science ®Google Scholar
• Weidlich L, Baethgen LF, Mayer LW, Moraes C, Klein CC, Nunes LS, Rios SD, Kmetzsch CI, Rossetti ML, Zaha A. 2008. High prevalence of Neisseria meningitidis hypervirulent lineages and emergence of W135:P1.5,2:ST-11 clone in Southern Brazil. J Infect. 57:324–31.
   PubMed Web of Science ®Google Scholar
• Weynants VE, Feron CM, Goraj KK, Bos MP, Denoël PA, Verlant VG, Tommassen J, Peak IR, Judd RC, Jennings MP, Poolman JT. 2007. Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis. Infect Immun. 75:5434–42.
   PubMed Web of Science ®Google Scholar
• Woodland DL. 2004. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol. 25:98–104.
   PubMed Web of Science ®Google Scholar
• Ying S, He J, Yu M, Zhang Y, Deng S, Zhang L, Xie M, Hu S. 2014. Recombinant Neisseria surface protein a is a potential vaccine candidate against Neisseria meningitidis serogroup B. Mol Med Rep. 10:1619–25.
   PubMed Web of Science ®Google Scholar
• Zimmermann P, Curtis N. 2019. Factors that influence the immune response to vaccination. Clin Microbiol Rev. 32:1–50.
   Web of Science ®Google Scholar